Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs... see more

TSX:TH - Post Discussion

Theratechnologies Inc > Financing?
View:
Post by xena555 on Jan 08, 2021 9:29am

Financing?

I may have missed a previous discussion on this, but aren't these guys going to have to rasie a bunch of money to conduct their trials? I'm wondering if that's why the analysts aren't being overly agressive right now.
Comment by SPCEO1 on Jan 08, 2021 11:48am
Yes, the trial they profiled yesterday is much larger, and therfore even more expensive, than what they initially were talking about. But a financing is what makes the analyst aggressively promote a stock. For an example go look at the run-up to the $125 million NGM just raised this week. In the week before, analysts were stumbling over themselves tor aise their price targets drammatically on the ...more